T
Protara Therapeutics, Inc.
TARACIK 0001359931NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-57.44M
Total Assets
$209.47M
Equity
$196.41M
Shares Out
54.08M
Op. Cash Flow
$-56.37M
Business
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative therapies for cancer and rare diseases. It is advancing two lead product candidates: TARA-002, an investigational Streptococcus pyogenes–derived cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational intravenous choline formulation for patients on parenteral support. Its principal programs are organized into oncology (NMIBC development and combination/systemic dosing studies) and rare disease (pediatric LMs and parenteral nutrition deficiency). Clinical trials are conducted primarily in the United States with sites in Canada, Argentina, Ukraine and European markets, and manufacturing is performed through U.S. cGMP contract development and manufacturing organizations under licenses and collaborations.
Summary from filing dated 2025-03-05
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 43 | 32 | 25 | 17 | 21 | |
| General and administrative | 22 | 17 | 19 | 21 | 26 | |
| Total operating expenses | 65 | 49 | 44 | 67 | 47 | |
| Income (Loss) from operations | −65 | −49 | −44 | −67 | −47 | |
| Interest and investment income (expense) | 6 | 4 | 3 | 1 | 237,000 | |
| Other income (expense) | 730,000 | 387,000 | — | — | — | |
| Other income (expense), net | 7 | 5 | 3 | 1 | 237,000 | |
| Net income (loss) | −57 | −45 | −40 | −66 | −47 | |
| Net unrealized gain (loss) on marketable debt securities | 88,000 | 33,000 | — | — | — | |
| Other comprehensive income (loss) | 88,000 | 33,000 | 657,000 | −477,000 | −211,000 | |
| Comprehensive income (loss) | −57 | −45 | −40 | −66 | −47 | |
| Net income (loss) per share attributable to common stockholders, basic (in Dollars per share) | −1.34 | −2.17 | −3.57 | −5.86 | −4.21 | |
| Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share) | −1.34 | −2.17 | −3.57 | −5.86 | −4.21 | |
| Weighted-average shares outstanding, basic (in Shares) | 43 | 21 | 11 | 11 | — | |
| Weighted-average shares outstanding, diluted (in Shares) | 43 | 21 | 11 | 11 | 11 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 50 | 163 | 40 | 24 | 36 | |
| Marketable debt securities | 106 | 7 | 26 | 60 | 56 | |
| Prepaid expenses and other current assets | 4 | 2 | 3 | 2 | 2 | |
| Total current assets | 160 | 172 | 69 | 86 | 93 | |
| Restricted cash, non-current | 745,000 | 745,000 | 745,000 | 745,000 | 745,000 | |
| Marketable debt securities, non-current | 42 | — | — | 18 | 39 | |
| Property and equipment, net | 759,000 | 1 | 1 | 2 | 2 | |
| Operating lease right-of-use asset | 3 | 4 | 5 | 6 | 7 | |
| Other assets | 3 | 3 | 3 | 644,000 | — | |
| Total assets | 209 | 181 | 79 | 113 | 173 | |
| Accounts payable | 3 | 4 | 2 | 2 | 954,000 | |
| Accrued expenses and other current liabilities | 6 | 5 | 3 | 3 | 2 | |
| Operating lease liability | 1 | 1 | 983,000 | 917,000 | 855,000 | |
| Total current liabilities | 11 | 11 | 6 | 6 | 4 | |
| Operating lease liability, non-current | 2 | 3 | 4 | 5 | 6 | |
| Total liabilities | 13 | 14 | 11 | 11 | 11 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2025 and 2024, 5,615 and 7,991 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | — | — | — | — | — | |
| Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 53,587,260 and 35,044,772 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 54,000 | 35,000 | 11,000 | 11,000 | 11,000 | |
| Additional paid-in capital | 499 | 412 | 269 | 263 | 256 | |
| Accumulated deficit | −302 | −245 | −200 | −160 | −94 | |
| Accumulated other comprehensive income (loss) | 90,000 | 2,000 | −31,000 | −688,000 | −211,000 | |
| Total stockholders equity | 196 | 167 | 68 | 102 | 162 | |
| Total liabilities and stockholders equity | 209 | 181 | 79 | 113 | 173 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 4 | 4 | 6 | 7 | 10 | |
| Operating lease right-of-use asset | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 362,000 | 332,000 | 341,000 | 248,000 | 117,000 | |
| Realized loss (gain) on redemption of marketable debt securities | −9,000 | — | — | — | — | |
| Amortization of premium (Accretion of discount) on marketable debt securities | −1 | −685,000 | −444,000 | 1 | 2 | |
| Prepaid expenses and other current assets | −2 | 1 | −1 | 265,000 | −418,000 | |
| Other assets | 322,000 | −328,000 | −2 | 222,000 | 295,000 | |
| Accounts payable | −873,000 | 1 | 848,000 | 631,000 | 40,000 | |
| Accrued expenses and other current liabilities | 821,000 | 3 | −505,000 | 748,000 | 576,000 | |
| Operating lease liabilities | −1 | −984,000 | −917,000 | — | — | |
| Net cash provided by (used in) operating activities | −56 | −36 | −38 | −26 | −35 | |
| Purchase of marketable debt securities | −205 | −29 | −12 | −44 | — | |
| Proceeds from maturity and redemption of marketable debt securities | 65 | 49 | 65 | 59 | — | |
| Purchase of property and equipment | −94,000 | −63,000 | −45,000 | −120,000 | −596,000 | |
| Net cash provided by (used in) investing activities | −139 | 19 | 53 | 15 | −98 | |
| Proceeds from December 2024 Public Offering, net of offering costs of $6,051 | — | 94 | — | — | — | |
| Proceeds from private placement, net of offering costs of $3,034 | — | 42 | — | — | — | |
| Proceeds from exercise of Underwriters Option in December 2024 Public Offering, net of offering costs of $214 | 3 | — | — | — | — | |
| Offering costs paid in connection with the December 2024 Public Offering | −614,000 | — | — | — | — | |
| Proceeds from December 2025 Public Offering, net of offering costs of $5,286 | 81 | — | — | — | — | |
| Proceeds from exercise of stock options | 21,000 | 135,000 | — | — | — | |
| Taxes paid related to net share settlement of restricted stock units | −185,000 | −83,000 | −91,000 | — | — | |
| Net cash provided by (used in) financing activities | 83 | 140 | −91,000 | −90,000 | −228,000 | |
| Net increase (decrease) in cash and cash equivalents and restricted cash | −113 | 123 | 15 | −12 | −133 | |
| Interest | — | — | — | — | — | |
| Income taxes | — | — | — | — | — | |
| Proceeds from public offering offering costs incurred but not paid | 526,000 | 614,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro